Inhibikase Therapeutics, Inc.
NASDAQ: IKT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Mark T. Iwicki
- Employees
- 35
- Headquarters
- Wilmington, United States
- IPO year
- 2020
- Market cap
- $246.9M
- Website
- https://www.inhibikase.com
Loading IKT…
Loading profile data…Frequently asked questions about IKT
What does Inhibikase Therapeutics, Inc. (IKT) do?
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resist...
Where does IKT trade?
Inhibikase Therapeutics, Inc. (IKT) trades on the NASDAQ.
What sector is IKT in?
Inhibikase Therapeutics, Inc. (IKT) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Inhibikase Therapeutics, Inc.?
Mark T. Iwicki is the chief executive officer of Inhibikase Therapeutics, Inc. (IKT).
Where is Inhibikase Therapeutics, Inc. headquartered?
Inhibikase Therapeutics, Inc. is headquartered in United States.
Does IKT pay a dividend?
Inhibikase Therapeutics, Inc. (IKT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IKT go public?
Inhibikase Therapeutics, Inc. (IKT) completed its initial public offering in 2020.